GlassScriptPhysician profile
Brad Eric Venghaus
NPI 1598101057
$6,648.02
in general payments reported to CMS, 2019-2025
38 companies · $1,602 in 2025
The $1,602 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $157 · 2021: $1,181 · 2022: $868 · 2023: $1,382 · 2024: $1,275 · 2025: $1,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,259.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $804.95 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $706.45 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Otsuka America Pharmaceutical, INC. | $592.57 | 2019-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $419.32 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $414.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $321.71 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $284.30 | 2020-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.16 | 2021-2025 | Jardiance |
| Gilead Sciences, INC. | $263.89 | 2021-2024 | |
| Medtronic, INC. | $246.62 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Pfizer INC. | $238.30 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.11 | 2021-2025 | Xifaxan |
| Exact Sciences Corporation | $173.24 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $167.37 | 2022-2025 | Quviviq, Quviviq |
| Nevro Corp. | $131.83 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $131.81 | 2021-2023 | Korlym |
| Sanofi-Aventis U.S. LLC | $119.15 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $118.09 | 2022-2025 | Spravato |
| Inspire Medical Systems, INC. | $105.02 | 2024-2025 | Inspire |
| Amgen INC. | $98.05 | 2022-2025 | Otezla, Repatha, Repatha |
| Viiv Healthcare Company | $70.80 | 2023-2025 | Apretude |
| Ibsa Pharma INC. | $70.19 | 2020-2024 | Tirosint, Licart |
| Abbott Laboratories | $66.16 | 2021-2024 | Freestyle Libre 3, Proclaim |
| Dexcom, INC. | $64.75 | 2024-2025 | Dexcom G6 Transmitter |
| Collegium Pharmaceutical, INC. | $53.00 | 2025 | Jornay Pm |
| Biogen, INC. | $51.52 | 2021-2025 | Leqembi |
| Currax Pharmaceuticals LLC | $49.51 | 2022-2025 | Contrave |
| Supernus Pharmaceuticals, INC. | $46.23 | 2024-2025 | Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $41.83 | 2022 | |
| Genentech USA, INC. | $41.66 | 2020-2021 | |
| Astellas Pharma US INC | $38.99 | 2023-2024 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $38.57 | 2023-2024 | Accrufer |
| Hologic Sales and Service, LLC | $38.24 | 2025 | Aptima |
| Abiomed | $36.67 | 2019 | |
| Azurity Pharmaceuticals, INC. | $29.86 | 2024 | Horizant |
| Janssen Biotech, INC. | $28.42 | 2019 | |
| Stryker Corporation | $17.99 | 2021 | |
| Axonics, INC. | $17.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Venghaus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.